NATCOPHARM Stock Overview
A pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs).
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
NATCO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,537.55 |
| 52 Week High | ₹1,584.95 |
| 52 Week Low | ₹724.20 |
| Beta | 0.54 |
| 11 Month Change | 12.42% |
| 3 Month Change | 58.45% |
| 1 Year Change | 70.46% |
| 33 Year Change | 56.88% |
| 5 Year Change | 163.53% |
| Change since IPO | 8,441.94% |
Recent News & Updates
Recent updates
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13
If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Shareholder Returns
| NATCOPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.7% | 2.4% | 1.0% |
| 1Y | 70.5% | 60.9% | 44.8% |
Return vs Industry: NATCOPHARM exceeded the Indian Pharmaceuticals industry which returned 60.9% over the past year.
Return vs Market: NATCOPHARM exceeded the Indian Market which returned 44.8% over the past year.
Price Volatility
| NATCOPHARM volatility | |
|---|---|
| NATCOPHARM Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: NATCOPHARM's share price has been volatile over the past 3 months.
Volatility Over Time: NATCOPHARM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 3,946 | Rajeev Nannapaneni | www.natcopharma.co.in |
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services.
NATCO Pharma Limited Fundamentals Summary
| NATCOPHARM fundamental statistics | |
|---|---|
| Market cap | ₹275.39b |
| Earnings (TTM) | ₹16.37b |
| Revenue (TTM) | ₹43.49b |
16.8x
P/E Ratio6.3x
P/S RatioIs NATCOPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NATCOPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹43.49b |
| Cost of Revenue | ₹7.01b |
| Gross Profit | ₹36.48b |
| Other Expenses | ₹20.12b |
| Earnings | ₹16.37b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 91.37 |
| Gross Margin | 83.89% |
| Net Profit Margin | 37.63% |
| Debt/Equity Ratio | 6.3% |
How did NATCOPHARM perform over the long term?
See historical performance and comparison